Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 24, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	326	78	7	47	191	4,212
Market Cap Growth	143.23%	965.79%	-84.63%	-75.15%	-95.47%	-77.67%
Enterprise Value	215	-1	-1	52	153	4,180
Last Close Price	18.00	7.43	9.10	1209.61	4895.96	7603.14
PS Ratio	1700.06	176.29	3.79	2.63	35.37	628.78
PB Ratio	3.51	0.58	1.00	-4.35	8.27	171.49
P/TBV Ratio	4.03	0.63	-	-	22.11	491.62
EV/Sales Ratio	1121.61	-	-	2.87	28.36	624.03
Debt / Equity Ratio	0.01	0.01	0.26	-1.98	1.53	0.06
Asset Turnover	0.00	0.01	0.07	0.32	0.09	0.17
Inventory Turnover	-	-	-	896.21	2444.83	2074.05
Quick Ratio	14.00	19.42	1.64	0.68	2.99	1.53
Current Ratio	14.28	19.95	1.82	0.74	3.11	1.71
Return on Equity (ROE)	-174.79%	-50.06%	-	-684.77%	-354.08%	-282.65%
Return on Assets (ROA)	-37.18%	-29.75%	-53.91%	-32.95%	-82.82%	-74.02%
Return on Capital (ROIC)	-71.36%	-35.69%	-146.88%	-54.11%	-121.58%	-122.42%
Return on Capital Employed (ROCE)	-56.80%	-28.40%	-143.20%	-266.10%	-136.20%	-165.80%
Earnings Yield	-30.54%	-45.18%	-432.43%	-87.80%	-44.19%	-1.51%
FCF Yield	-16.01%	-63.10%	-422.75%	-56.58%	-37.19%	-0.96%
Buyback Yield / Dilution	-450.90%	-2599.19%	-608.45%	-8.32%	-41.86%	-28.52%

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q